
Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

BioNTech bags Instadeep for £562m
According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

Vésale Bioscience wins R&D grant
Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...